



ASX Announcement

1 February 2019

Creso Creates Partnership with National University of Colombia in Bogota and Signs Dr Ricardo Salazar Lopez as Primary Medical Advisor

- Creso will leverage an expert medical network to support the development and validation of its therapeutic and nutraceutical products.
- Creso is licensed to complete research and development, cultivate, manufacture, distribute and export. Creso's nursery is in the final stages of genetic registration and Creso is awaiting final word on quota issued by the authorities.
- Dr Salazar will act as Creso' Primary Medical Advisor and will focus on formulations targeted at specific ailments and leverage the National University to develop clinical evidence in support of all therapeutic products.
- Dr Salazar is a Member of the Colombian Academy of Medicine, a distinction limited to a handful of physicians
- Colombia represents a significant strategic foothold for Creso as it will serve as a low cost source of psycho-active and non psycho-active medicinal cannabis for South America and Europe

Creso Pharma Limited (ASX: "CPH", the "Company" or "Creso") has recently welcomed Dr Ricardo Salazar to the team as Primary Medical Advisor in Colombia. Dr Salazar is a distinguished Colombian physician with strong connections to the academy of Medicine and the National University of Colombia of Bogota.

Colombia is very invested in developing the cannabis industry on many fronts. "The Colombian government is well advanced on the regulation of medicinal cannabis and is anxious to be distinguished globally for more than cultivation" said Dr Salazar.

"Colombia is well known for its ideal climate for cultivation of cannabis, to develop the industry beyond exportation of cultivated crop derivatives, Colombia will also need to build its reputation for clinical expertise and product development. The objective being to export not just low cost extracts for the world but create jobs and revenues for Colombia as a producer of therapeutics and value added cannabis products."

"To date Colombia has been flying under the radar for Creso" says John Griese Chief Operating Officer. "Creso's Colombian assets are extremely rich and our team in Colombia is very well established and connected to the cannabis, medical and pharmaceutical industries. Combining with the medical community provides access to expertise not found outside Israel. Our strategy will unfold rapidly and Creso will be a premier



Colombia cannabis leader and be in the unique position to leverage this capability in their global network.”

Dr. Miri Halperin Wernli, Creso’s CEO and Co-Founder is excited to partner with Dr Salazar and the National University.

“Creso has been in talks with Dr Salazar for some time now. His passion for cannabis and its capabilities, his deep technical expertise and his ability to lead and influence across the medical, academic and regulatory community is invaluable. This is a perfect match for Creso Pharma. ”

Dr Ricardo Salazar Lopez is an experienced and qualified physician and is recognized as a cornerstone in the Colombian medical community. The Doctor is a member of the National University of Colombia, Director of the Education Commission of the Colombian National Academy of Medicine, Teacher at the National, Javeriana, Rosario Universities and Sabana, and is an early member of the Colombian National Academy of Medicine.

Dr Salazar has trained abroad and is a member of the American Society of Plastic Surgeons and is a founding member of “Colombo” the French medical Association.

---END---

About Creso Pharma

www.cresopharma.com

Creso Pharma brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp de-rived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

Corporate Enquiries

EverBlu Capital

Level 39, Aurora Place

88 Phillip Street, Sydney NSW 2000

E: info@everblucapital.com

T: +61 (02) 8249 0000